title: Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
abstract: Gemcitabine and S-1 are drugs commonly used for treating locally advanced pancreatic cancer (LAPC). However, the safety and efficacy of combination of these agents for induction chemotherapy (IC) followed by chemoradiotherapy are not well-defined.
  
  
  
  Fifteen patients with LAPC (IC-CRT group) were treated with gemcitabine and S-1 IC, followed by S-1 chemoradiotherapy. The clinical outcomes were compared to a cohort of 38 patients who received chemoradiotherapy alone (CRT group).
  
  
  
  Disease control rates in the CRT and IC-CRT groups were 84% and 93%, respectively (p=0.024). The median time of disease progression was 10.8 and 15.4 months in the CRT and IC-CRT group, respectively (p=0.043). The median overall survival time was longer in the IC-CRT group compared to CRT (23.4 vs. 17.3 months), but this increase was not statistically significant.
  
  
  
  Gemcitabine and S-1 combination chemotherapy, followed by CRT, is a promising IC regimen for treating LAPC.
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan kmaemura@hotmail.co.jp.
authors.forename: Kosei
authors.initials: K
authors.lastname: Maemura
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Mataki
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kurahara
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Yota
authors.initials: Y
authors.lastname: Kawasaki
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Iino
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sakoda
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Yasuto
authors.initials: Y
authors.lastname: Uchikado
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Takaaki
authors.initials: T
authors.lastname: Arigami
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Uenosono
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Mori
authors.affiliation: Clinical Oncology, Kagoshima University, Kagoshima, Japan.
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ueno
authors.affiliation: Graduate School of Health Sciences, Kagoshima University, Kagoshima, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shinchi
authors.affiliation: Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University, Kagoshima, Japan.
authors.forename: Shoji
authors.initials: S
authors.lastname: Natsugoe
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000009:adverse effects; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000628:therapy*; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine
keywords: Induction chemotherapy; S-1; chemoradiotherapy; gemcitabine; pancreatic cancer